Curated coverage for opioid with top developments, timeline context, and connected threads.
A new class of oral non-opioid pain drugs is in late-stage trials. Here is the mechanism, the clinical results, and when they might reach patients who have exhausted current options.
EuroBulletin24 Editorial Desk | Linked source
Suzetrigine (Journavax) was FDA-approved in January 2025 and is now reshaping pain management. Here is what it is, how it works differently from opioids, and who it could help.